Shenzhen Salubris Pharmaceuticals Co., Ltd. (SHE:002294)

SHE:002294 Revenue

Shenzhen Salubris Pharmaceuticals had revenue of 1.26B CNY in the quarter ending September 30, 2026, with 13.81% growth. This brings the company's total for the last twelve months to 4.85B, up 14.15% year-over-year. In the year 2025, Shenzhen Salubris Pharmaceuticals had annual revenue of 4.35B with 8.48% growth. That makes Shenzhen Salubris Pharmaceuticals the 9,186th largest company in the world by revenue and 1,459th in China.

• Revenue (ttm): 4.85B
• Revenue Growth: +14.15%
• P/S Ratio: 6.81
• Revenue / Employee: 1.19M
• Employees: 4,087
• Market Cap: 33.07B

Revenue Chart

Chart

Chart

Revenue by Segment

Chart

• Pharmaceutical Manufacturing 3.97B 91.3%
• Medical Devices 379.94M 8.7%

Fiscal year ended Dec 31, 2025 See the full SHE:002294 breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	4.35B	340.43M	8.48%
Dec 31, 2024	4.01B	646.89M	19.22%
Dec 31, 2023	3.37B	-116.67M	-3.35%
Jan 1, 2023	3.48B	423.62M	13.85%
Jan 1, 2022	3.06B	319.83M	11.68%

Data Source: S&P Global Market Intelligence Last updated: Oct 26, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 31, 2026

Data Sources Report a data error